18 slides from Krka, D. D., Novo Mesto's earnings presentation, March 2026
Slide 1: Krka Group Presentation FY 2025 Business Performance Results
KRKA GROUP PRESENTATION FY 2025 Business Performance Results March 2026
Slide 2: Krka Group Business Performance Results
Krka Group Business Performance Results 2025 unaudited financial statements highlights ✓ Record sales: €2,041m; +7% yoy Worldwide, Krka’s medicines are used by more than 100 million ✓ EBITDA margin: 27.4%; EBITDA of €559m +7% yoy people ✓ EBIT margin: 22.8%; EBIT of €465m +9% yoy ✓ Net profit margin
Slide 3: Krka Group Sales by Regions
Krka Group Sales by Regions Present in more than 70 countries worldwide FY2025: EUR 2,034 million of goods and services Largest markets – Russian Federation: +13% 333 387 347 373 422 (+7 % yoy; + EUR 134.2 million) Sales of pharmaceutical and chemical activities in millions of EUR 2021 2022 2023 202
Slide 4: Broad Product Portfolio
Broad Product Portfolio Rx remains the most important product group, with EUR +124.4 million sales increase Majority of sales for Health-resort & tourist companion animals services Animal health products EUR 54.2m +10 % Rx EUR 114.7m (EUR +4.9m) +3 % primarily for chronical diseases (EUR +2.8m) 2.7%
Slide 5: Research and Development
Research and Development Innovative branded generic producer, with own R&D Competitive advantage – Overcoming 2 regulatory challenges by leveraging established 13 OTC 60% expertise to introduce innovative products Prescription New products 2 40% R&D products Our products are based on: VET Lifecycle
Slide 6: Krka's Innovative Medicines
Krka’s Innovative Medicines Innovative branded generic producer, with own R&D ADVANCED UNIQUE STATE-OF-THE-ART UNIQUE >150 PHARMACEUTICAL SINGLE PILL EQUIPMENT STRENGTHS FORMULATIONS COMBINATIONS Delivering the most demanding Great possibility of Tailoring the Synergistic action & projects in terms
Slide 7: Investments in 2025
Investments in 2025 Investments are focused on strengthening the business model of vertical integration Investments are primarily directed toward increasing Investments in Progress and technologically upgrading production capacities, NOTOL and NOTOL 2 Slovenia, Novo mesto as well as capacities for d
Slide 8: Financial results & margins
Financial results & margins The highest EBITDA, EBIT, and net profit in Krka’s history EUR thousand 2025 (%) 2024 (%) YoY Revenue 2,041,025 100 1,909,544 100 7% Costs of goods sold 858,019 42.0 815,661 42.7 5% Gross profit 1,183,006 58.0 1,093,883 57.3 8% Other operating income 8,167 0.4 7,130 0.4 1
Slide 9: FX Impact
FX Impact Positive contribution of RUB on NFI in 2025 • The effect of currency movements on the Group’s net EUR/RUB 2020–2025 financial result, which includes exchange rate differences and EURm EURRUB the impact of derivative financial instruments, was positive in 60 +€51.9m 160 2025. NFI EURRUB 140
Slide 10: Performance Indicators
Performance Indicators Maintaining long-term momentum Revenue € million EBITDA in € million 600 558 2,500 488 504 520 1910 2041 464 2,000 1717 1806 500 1565 400 1,500 300 1,000 200 5y average (2021-2025) 500 5Y CAGR 6% 100 EBITDA margin: 28.1% 0 0 2021 2022 2023 2024 2025 2021 2022 2023 2024 2025 Ne
Slide 11: Dividend Policy and Share Buyback
Dividend Policy and Share Buyback Management committed to stable capital allocation DPS and dividend yield* for the business year Treasury shares Continually increasing dividend payout policy Repurchasing treasury shares whenever possible 9.00 8% 8.00 8.0% 7.4% 7.6% 10Y CAGR 12.7% 7% 7.00 6.4% 6% 5.
Slide 12: 2025 Preliminary results and 2026 Guidance
2025 Preliminary results and 2026 Guidance Guidance in line with strategic goals Sales (EUR million) Net income (EUR million) Guidance for 2026 2.144 404 405 2,014 2.041 365 SALES € 2,144m Prvotna 2025 2025 napoved Initial guidance 2025 2026 Napoved Plan 2025 2025 Initial guidance Prvotna napoved 20
Slide 13: Krka Group Development Strategy 2026-2030
Krka Group Development Strategy 2026-2030 Amplifying our strategic foundation built on three strategic pillars PROVIDING VERTICAL INTEGRATION VALUE CREATION ACCESS TO MEDICINES We supply We leverage We create Providing uninterrupted and Ensuring sufficient quantities of Positive impacts of our opera
Slide 14: Krka Group Development Strategy 2026-2030
Krka Group Development Strategy 2026-2030 Ensure uninterrupted supply of sufficient quantities Ensure uninterrupted supply of sufficient Ensure the sufficient quantities of Ensure that the positive impacts of our quantities of high-quality, safe, and products, and further strategically operations re
Slide 15: Summary: key strategic objectives
Krka Group Development Strategy 2026-2030 Summary: key strategic objectives To achieve Annual sales revenue allocated ≥ 5% Average annual sales growth 10% to R&D > 25% Average EBITDA margin Strengthen our position among the Average annual CAPEX allocated Net profit of majority shareholders Top 5 top
Slide 16: Long-term Stable Growth
Long-term Stable Growth Growing faster than the global pharmaceutical market Revenue growth CAGR (2005–2025) 7.2% 2,500 20 Net income growth CAGR (2005–2025) 9.1% 18 Pharmaceutical market growth CAGR (2005–2024) 5.8% 2,000 16 Quantities in billion 14 1,500 12 EUR million 10 1,000 8 6 500 4 2 0 0 200
Slide 17: Disclaimer
Disclaimer The information, statements or data contained in this presentation has been prepared by Krka, tovarna zdravil, d. d., Novo mesto (hereinafter: the Company) and has been prepared solely for the purpose of informative presentation of the Company business operations. The presentation is not
Slide 18: Living a healthy life.
Living a healthy life.